Given the observed DCIS risks, and the lifetime risk of DCIS in women (i.e., approximately 1%), BRCA1 carriers have only a modest increase in the risk of DCIS (about 2%), and BRCA2 carriers are at moderate to high lifetime risk of DCIS (above 4%). This evidence concerns the gene BRCA2 and ductal breast carcinoma in situ.